Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...

Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 13,931 calls trading, 1.4x expected, and implied vol increasing over 13 ...

Cramer stated on Mad Money at the end of last week's trading that Recursion's stock performance has "been disastrous" since ...

Around the middle of February, shares of Recursion Pharmaceuticals bounded higher after the company reported phase 2 results ...

Explore why Recursion Pharmaceuticals' AI-driven drug discovery faces challenges in revenue growth, governance, and investor ...

We recently published an article titled Jim Cramer's Latest Lightning Round: 8 Stocks in Focus. In this article, we are going ...

Shares of Nvidia-backed Recursion Pharmaceuticals Inc. (RXRX) ended Friday lower, extending weekly losses past 21% after missing Wall Street estimates on both revenue and profit in its latest ...

Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

The Gothic Recursion collection may seem like original designs from Marvel Rivals, but Black Panther's newest skin has comic ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage biotech company, which is a pioneer in using artificial intelligence ...